CG
AKRO

Cutler Group’s Akero Therapeutics AKRO Stock Holding History

Cutler Group’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,600
Closed -$112K – 3557
2023
Q3 		$112K Hold
10,600
– – 0.01% 1065
2023
Q2 		$54K Sell
10,600
-1,700
-14% -$77.9K 0.01% 1241
2023
Q1 		$59K Sell
12,300
-7,100
-37% -$317K 0.01% 1238
2022
Q4 		$297K Buy
19,400
+8,200
+73% +$351K 0.03% 617
2022
Q3 		$61K Buy
+11,200
New +$171K ﹤0.01% 1754

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Cutler Group's AKRO Position: Q1 2024 in Review

Cutler Group increased its Akero Therapeutics (AKRO) stake by 100% in Q1 2024, buying an estimated $7.21K and bringing the position to 600 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #1103.

Cutler Group first reported a position in AKRO in Q1 2020 and has held it in 7 quarters since. The position peaked at $23K in Q1 2021. 173 funds tracked by Wall St. Rank hold AKRO as of Q1 2024.

  • Cutler Group held 600 shares of Akero Therapeutics worth $15K as of Q1 2024.
  • Cutler Group bought 300 Akero Therapeutics shares in Q1 2024, an estimated $7.21K.
  • Akero Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1103 holding.
  • Cutler Group first reported a position in Akero Therapeutics in Q1 2020 and has held it in 7 quarters since.
  • Cutler Group's Akero Therapeutics position peaked at $23K in Q1 2021.
  • 173 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.